Is Heartflow, Inc. Common Stock (HTFL) a Buy, Sell, or Hold?
NASDAQ : HTFL
Heartflow, Inc. Common Stock
$24.0395 USD
-$0.19 (-0.79%)
- Volume
- 211.85K
- Average Volume
- 1.48M
- Market Capitalization
- $2.07B
- P/E Ratio
- -27.30
- Dividend Yield
- 0.00%
- Price Target
- $37.00
- Year High
- $41.22
- Year Low
- $20.13
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.57
Company Overview
NASDAQ
John Farquhar
Medical - Healthcare Information Services
Healthcare
HTFL
843
US
USD
Liquidity Metrics
0.09
5.57
5.57
0.52
0.00
Sales & Valuation
$176.03M
10.83
31.01
-27.00
-0.21
Profitability
-$0.32
-$116.79M
-58.42%
-58.45%
830.46%
-32.51%
P/E Metrics
-27.30
-0.56
-0.56
Analyst Price Target & Rating
$37.00
$40.00
$37.00
2/5
4 Analysts
-35.03%
Financial Health Scores
18.26
5/9
$173.81M
$344.02M
$58.31M
-$101.8M
Key Metrics (TTM)
$2.1B
10.95
-22.57
5.57
830.46%
-21.94%
-1.25%
-3.67%
18 days
Company Executives
| Name | Title |
|---|---|
| Angela Ahmad | Chief Legal & Compliance Officer |
| Kathleen Carey | Senior Vice President of Operations |
| Vikram Verghese | Chief Financial Officer |
| Campbell Rogers FACC | Chief Medical Officer & Executive Vice President |
| John Henry Stevens | Co-Founder |
| Mhairi L. Jones | Chief Accounting Officer |
| Justin Cambra | Chief Technology Officer |
| Nicholas S. Laudico | Vice President of Investor Relations |
| Shivanth Bhaskaran | Chief Commercial Operations & Customer Success Officer |
| John Farquhar | President, Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Heartflow, Inc. Common Stock (NASDAQ:HTFL) Stock
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditiona ... l non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
What Does the HeartFlow CEO's Sale of Over 20,000 Company Shares Mean for Investors?
2026-07-15 08:10:01
The medical technology company reported a notable insider sale in recent filings.
HeartFlow: A Premium AI Diagnostics Story
2026-07-11 23:10:20
I recommend a buy rating for HeartFlow, Inc. due to its strong clinical workflow integration and expanding product suite. HTFL's AI-enabled platform, anchored by FFRCT and Plaque Analysis, drives adoption, monetization, and workflow efficiency in coronary artery disease diagnosis. Plaque Analysis, validated and soon to have its own billing code, broadens HTFL's addressable market and supports incremental revenue growth from existing CCTA scans.
2026-07-09 08:00:00
Heartflow Plaque Staging TM , the only staging tool based on total plaque volume * , is now included with every Heartflow Plaque Analysis Data from over 36,000 patients validate the accuracy, reproducibility and utility of Heartflow Plaque Analysis SAN FRANCISCO, July 09, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced eight new datasets from clinical studies spanning more than 36,000 patients will be presented at the Society of Cardiovascular Computed Tomography (SCCT) 2026 Annual Scientific Meeting taking place July 9-12, 2026 in San Diego. These studies reveal over 50% of symptomatic patients with zero coronary artery calcium (CAC) harbor significant non-calcified plaque that traditional CAC scoring cannot detect.
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
2026-07-08 17:21:25
Heartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data for heart disease. Omeros is launching its first commercial product, Yartemlea, while maintaining a pipeline focused on rare diseases.
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
2026-07-04 09:44:59
Heartflow leverages AI-enabled software to dominate the non-invasive coronary diagnostic market, backed by a stable base of over 1,450 accounts. Iovance Biotherapeutics is pioneering personalized TIL therapies for cancer, backed by centralized manufacturing and significant revenue growth from its lead products.
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
2026-06-24 14:45:21
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
Baron Discovery Fund Q1 2026: Who Moved The Needle
2026-06-08 01:35:00
In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. Advanced Energy Industries, Inc.'s stock rose during the quarter as the market began to appreciate the strength that the company would see in both its data center and semiconductor end markets. Baron Discovery Fund sold its investment in Intapp, Inc. in the quarter as the team believes that its other software holdings have better overall competitive advantages.
Is HeartFlow Stock a Buy After an Institutional Investor Initiated a Position Worth $2.7 Million?
2026-05-31 01:42:02
HeartFlow delivers AI-powered, non-invasive cardiac diagnostics for hospitals and cardiology clinics using proprietary imaging technology.
Frequently Asked Questions
-
What is the current Heartflow, Inc. Common Stock (HTFL) stock price?
-
Heartflow, Inc. Common Stock(NASDAQ:HTFL) stock price is $24.0395 in the last trading session. During the trading session, HTFL stock reached the peak price of $41.223 while $20.13 was the lowest point it dropped to. The percentage change in HTFL stock occurred in the recent session was --0.79% while the dollar amount for the price change in HTFL stock was -$0.19.
-
HTFL's industry and sector of operation?
-
The NASDAQ listed HTFL is part of Medical - Healthcare Information Services industry that operates in the broader Healthcare sector.
-
Who are the executives of HTFL?
-
Angela Ahmad | Chief Legal & Compliance Officer
Kathleen Carey | Senior Vice President of Operations
Vikram Verghese | Chief Financial Officer
Campbell Rogers FACC | Chief Medical Officer & Executive Vice President
John Henry Stevens | Co-Founder -
How many employees does HTFL have?
-
Number of HTFL employees currently stands at 843. HTFL operates from 331 E. Evelyn Avenue, Mountain View, CA 94041, US.
-
Link for HTFL official website?
-
Official Website of HTFL is: https://www.heartflow.com
-
How do I contact HTFL?
-
HTFL could be contacted at phone #650-241-1221 and can also be accessed through its website. HTFL operates from 331 E. Evelyn Avenue, Mountain View, CA 94041, US.
-
How many shares of HTFL are traded daily?
-
The average number of HTFL shares traded daily for last 3 months was 1.48M.
-
What is the market cap of HTFL currently?
-
The market value of HTFL currently stands at $2.07B with its latest stock price at $24.0395